Dr. Fyffe-Maricich received her PhD in Human and Molecular Genetics from Baylor
College of Medicine. She completed her graduate training in the lab of Dr. Huda Zoghbi
where she studied the contribution of specific neuronal subpopulations to the underlying
biology of Rett Syndrome. Following her postdoctoral training at Case Western
Reserve University in the field of central nervous system myelin biology, she joined the
faculty at the University of Pittsburgh School of Medicine as an Assistant Professor of
Pediatric Neurology. Her laboratory focused on using genetic mouse models to
understand the biology of MAP kinase signaling during oligodendrocyte development
and in the repair of demyelinating lesions with the ultimate goal of finding novel
treatments for patients with Multiple Sclerosis. Sharyl’s work was supported by the
National Multiple Sclerosis Society and NIH R01 funding from the National Institute of
Neurological Disorders and Stroke (NINDS).

In 2016, Sharyl joined Ultragenyx Pharmaceutical, a commercial-stage
biopharmaceutical company focused on developing novel and transformative treatments
for patients with rare diseases, to lead their Molecular Biology Research team. As a
trained neuroscientist, she also oversees the company’s preclinical research for all CNS
programs and she is the team lead for a gene therapy program for the treatment of
CDKL5 Deficiency Disorder.